BI 1584862

DRUG6 trials

Sponsors

Boehringer Ingelheim

Conditions

Geographic AtrophyHealthyHepatic Insufficiency

Phase 1

A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without Food

CompletedNCT05520827

Boehringer IngelheimHealthy

Start: 2022-09-29End: 2023-03-06Updated: 2023-03-09

A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men

CompletedNCT06006598

Boehringer IngelheimHealthy

Start: 2023-08-28End: 2024-05-05Updated: 2024-05-14

A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood

CompletedNCT06041438

Boehringer IngelheimHealthy

Start: 2023-09-29End: 2023-11-10Updated: 2026-06-03

A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated

CompletedNCT06148948

Boehringer IngelheimHealthy

Start: 2023-12-25End: 2024-05-21Updated: 2024-11-13

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

CompletedNCT06957756

Boehringer IngelheimHepatic Insufficiency

Start: 2025-08-06End: 2026-05-21Updated: 2026-07-07

Phase 2

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Active, not recruitingNCT06769048

Boehringer IngelheimGeographic Atrophy

Start: 2025-01-31End: 2027-01-05Updated: 2026-07-28